ALNEO included patients with potentially resectable disease and treated them with neoadjuvant alectinib for two cycles, ...

Our findings do not suggest high utilization of neoadjuvant chemotherapy is associated with a trade-off between perioperative and long-term outcomes,” the researchers wrote.

Adding an immune checkpoint inhibitor to neoadjuvant chemotherapy can improve pathologic complete response rates and may improve survival in patients with muscle-invasive bladder cancer, research ...

A recent meta-analysis reveals no link between pathologic complete response and long-term survival in rectal cancer, challenging its use as a surrogate endpoint.

Could endocrine therapy plus a CDK4/6 inhibitor offer a viable chemo-sparing option in hormone receptor (HR)-positive/HER2-positive breast cancer?

IMUNON, Inc. (IMNN) said on Wednesday its first patient has been dosed with the firm’s lead candidate, IMNN-001, as part of a ...

In this symposium, Frank Griesinger, Cecilia Pompili, and Jesme Fox discussed the latest evidence for neoadjuvant ...

In May 2025, Natera announced outcomes from a study assessing the Signatera MRD test in those with soft tissue and bone ...

If approved, the expanded label builds on TEVIMBRA’s momentum in lung cancer with EU approvals already in NSCLC and SCLC indications across both first- and second-line settings BeOne Medicines Ltd.

Total neoadjuvant therapy demonstrates consistent real-world efficacy across regimens in patients with locally advanced ...

Revised Phase 2 Strategy Targets Event-Free Survival in Primary Head and Neck Cancer through Checkpoint Inhibitor Combination ...

Triple-negative breast cancer (TNBC) comprises 10–15% of all breast cancers. It is a very heterogeneous disease, ...